The DNTTIP1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human ovarian carcinoma epithelial cell line A2780, featuring disruption of the DNTTIP1 gene. This polyclonal knockout model provides a heterogeneous pool of edited cells for functional studies of DNTTIP1 in DNA repair and chromatin organization.
The A2780 cell line is a well-established model of human ovarian adenocarcinoma, widely used in ovarian cancer research, particularly in studies of chemoresistance and tumor progression. These epithelial cells retain key characteristics of high-grade serous ovarian carcinoma and are valuable for investigating DNA damage responses and therapeutic vulnerabilities.
DNTTIP1 encodes a protein that directly interacts with terminal deoxynucleotidyl transferase (DNTT/TdT) to regulate template-independent nucleotide addition during non-homologous end joining (NHEJ) and V(D)J recombination. The DNTTIP1 protein functions within the DNA damage response network, interacting with DNA repair factors including DNA polymerase mu and DNA ligase IV. Upstream, TP53 and other DNA damage-responsive transcription factors regulate DNTTIP1 expression. DNTTIP1-mediated control of TdT activity influences DNA repair efficiency and genomic stability, linking this gene to chromatin remodeling and the broader DNA repair machinery involving XRCC4, DNA-PKcs, and Artemis.
In A2780 ovarian cancer cells, DNTTIP1 disruption may impair double-strand break repair, potentially increasing genomic instability and altering sensitivity to DNA-damaging agents. This polyclonal knockout population enables investigation of DNTTIP1-dependent DNA repair mechanisms in a chemoresistant ovarian cancer context, offering a tool to dissect how altered DNA repair pathways contribute to drug resistance and cancer cell survival.
Typical research applications include DNA repair pathway analysis, ovarian cancer biology, chemoresistance mechanism studies, and functional genomics screens. Representative assays include western blotting, immunofluorescence staining of ??H2AX foci, clonogenic survival assays, comet assays, drug sensitivity profiling with cisplatin or PARP inhibitors, and transcriptomic analysis by RNA-seq. For further information or to inquire about this product, please contact Ascent Research.
